Forum Registration Open: Capital Empowering the Upgrade of Medical AI Industry

Event Theme:Capital Fuels the Upgrading of the Medical AI Industry

Time:October 28, 2018 8:30-12:30

Location:Hongbin Hall, Jinjiang Hotel, No. 80, Section 2, Renmin South Road, Chengdu, Sichuan Province

Forum Organizer:BOC Group Investment Company Limited

Co-organizers of the Forum:VCBeat

In recent years, artificial intelligence has been applied to many areas, including medical imaging recognition, computer-aided diagnosis, surgical procedures, gene sequencing, and healthcare big data. The issuance of the "New Generation Artificial Intelligence Development Plan" by the State Council in 2017 sent a strong positive signal to the entire health industry, making "AI + Healthcare" a highly sought-after trend. However, due to various issues within China's current healthcare service system, AI in healthcare also faces significant challenges. Against this backdrop, BOC Group Investment Co., Ltd. hostedForum on Capital Empowering the Industrial Upgrading of Medical AILaunched recently,The forum will be held in Chengdu on October 28, 2018.。

This forum brings together financial institutions in the healthcare investment sector, innovative healthcare enterprises, and renowned medical experts to engage in professional and in-depth discussions on topics such as AI-assisted diagnosis, AI-enabled healthcare, development trends, commercial viability, and capital investment opportunities.

BOC Group Investment Company Limited is a wholly-owned subsidiary of Bank of China, incorporated in Hong Kong in December 1984. As the professional investment management arm of Bank of China, BOC Investment engages in diverse investment activities across Hong Kong, Macao, mainland China, and overseas markets, with investments spanning sectors such as healthcare, consumer goods, energy, transportation, and finance. Through years of persistent effort and pioneering development, BOC Investment has leveraged Bank of China’s substantial financial strength and extensive business network to harness synergies, seize emerging opportunities, and actively expand its operations. The company has achieved remarkable performance in equity investments, fund investment and management, real estate investment and management, and distressed asset investment. Its assets under management exceed HK$180 billion.

Song Anlan — Partner at SoftBank China / Head of Technology Sector Investments

Song Anlan,Joined SoftBank China in January 2000, primarily responsible for the technology sector.Investment and management; currently serves as a director for multiple high-tech companies. Prior to joining SoftBank China, he wasA founding member of UTStarcom, where he served as Chief Information Officer; he also held the position of Chief Technology Officer at MDC Telecom and was a director and founder of companies such as GDS. Previously, he served as an Assistant Professor in the Department of Electrical Engineering at the University of Connecticut, USA, engaging in research and teaching in the fields of computer networks and information systems. Dr. Song Anlan holds bachelor’s and master’s degrees from the Department of Automation at Tsinghua University, as well as a doctoral degree from the School of Economics and Management at Tsinghua University.

Zhang Jianbin——Partner, IDG Capital

Jianbin Zhang joined IDG Capital in 2009. He focuses on investments in pharmaceuticals, diagnostic reagents, medical devices, and healthcare services, and has participated in and led the investment of multiple healthcare projects. With extensive experience in the biomedical industry, he has previously worked in new drug technology development, channel sales, pharmaceutical marketing, and corporate management.

Feng Tang— Senior Managing Director, CITIC Capital

Feng Tang, Senior Managing Director and Head of Healthcare at CITIC Capital, holds an MBA from Goizueta Business School at Emory University in the United States and a Doctor of Medicine (M.D.) degree from Peking Union Medical College in China. He previously served as Chief Executive Officer of China Resources Healthcare Group Co., Ltd. and General Manager of the Strategy Management Department of China Resources (Group) Co., Ltd.

Cao Yibo—— Managing Director, Sequoia Capital

Cao Yibo, Managing Director at Sequoia Capital China, holds a Master’s degree in Pharmaceutical Administration and a Bachelor’s degree in Pharmacy from Peking University. Prior to joining Sequoia, he was involved in most of VIVO Capital’s investment projects in China starting from its Fund VII, and served as a director at Smiccon and the Gengmei APP.

Qian Jianzhong——Chairman of EDDA Technology

Dr. Jianzhong Qian, Founder and Chairman of EDDA Technology, is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He has long been engaged in the field of medical devices and artificial intelligence computer vision for intelligent medical image analysis. Dr. Qian led the establishment of EDDA Technology, which is dedicated to artificial intelligence and precision medicine. The company pioneered the IQQA empowerment platform, a new generation of proprietary technology that “brings AI into the operating room.” This platform covers the entire cycle of diagnosis and treatment management, providing comprehensive, multi-level solutions for precision diagnosis and therapy. The company’s product series have received approval from China’s CFDA and the U.S. FDA. They are currently used clinically in over one hundred renowned hospitals both domestically and internationally, with more than 45,000 successful cases worldwide and over 250 independent clinical publications, earning significant market recognition.

Fan Li——Vice President, EDDA Technology

Dr. Li Fan, Co-founder and Vice President of EDDA Technology, has been engaged in research and clinical applications of artificial intelligence, computer vision, and other technologies in the field of medical imaging for over 20 years. At EDDA Technology, he led and spearheaded product definition, technical positioning, algorithm development, and clinical collaborations for a series of new intelligent diagnostic and therapeutic products within the IQQA® enablement platform. These applications cover the entire cycle of diagnosis and treatment management, including early cancer detection, preoperative assessment, surgical planning, intraoperative navigation reference, and postoperative follow-up evaluation. The products have received approval from the U.S. FDA and China’s CFDA (now NMPA) and have gained widespread clinical application and recognition.

Sun Xiaorong——Chairman and General Manager of Landin High-Tech

Sun Xiaorong completed her eight-year undergraduate and master’s medical education in China, and pursued her PhD and postdoctoral research in Australia and the United States. The “Landing” robot developed by her team at Landing has received certification from China’s CFDA, the U.S. FDA, and the EU CE. She pioneered the migration of third-party clinical laboratory services for cytopathology to a cloud-based platform.

Yang Cuijun——Founder and CEO of Yiyu Technology

Yang Cuijun, Founder/CEO of Shanghai Yiyu Technology Co., Ltd., Adjunct Professor at Shanghai Jiao Tong University, graduated with a degree in Electrical Engineering from Virginia Tech in the United States.Yiyu Technology is the first Chinese company to primarily target the high-end innovative medical device markets in developed countries across Europe and North America. It possesses multiple globally leading innovative medical devices for diabetes management and has fully entered the health insurance reimbursement markets of these developed regions.

Huan Dandan— Vice President and Board Secretary of Anhan Medical

Huan Dandan, an expert in computer system architecture and chip design, holds a Ph.D. from the Institute of Computing Technology, Chinese Academy of Sciences. She is a recipient of the 19th China Association for Science and Technology Qiushi Award for Outstanding Young Achievements in Technology Transfer and was named to Forbes China’s 2018 list of “25 Under 30” Potential Women in Business. As principal investigator, she has led two projects funded by the National Natural Science Foundation of China, all of which have been successfully commercialized.

Song Jie——Founder/CEO of Xishi Yigou

Song Jie, M.D. & EMBA (CEIBS), Founder and CEO of Xishi Yigou. Since early 2015, he has collaborated with the team of Dr. Wu Ren, a renowned international AI scientist, to conduct R&D on AI technologies for medical imaging. With a focus on practical clinical applications and delivering products as hardware-based medical devices, Xishi Yigou has achieved significant R&D outcomes in endoscopic imaging, ultrasound, and CT. Notably, its AI technology for digestive endoscopy provides comprehensive technical coverage across the entire gastrointestinal tract, including the small intestine, addressing more than one hundred clinically high-value diseases spanning six major categories. Currently, multiple products from Xishi Yigou have demonstrated clinical application value.

Wang Dong——Director of the Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital

Wang Dong, Chief Physician, Professor, Master’s Supervisor; Director of the Center for Robotic Minimally Invasive Surgery at Sichuan Provincial People’s Hospital; Chinese Director of the Sino-German Cooperative Center for Robotic Surgery; Academic and Technical Leader and Chief Expert in Surgery appointed by the Sichuan Provincial Health and Family Planning Commission; Chairman of the Committee on Medical Robots and Medical Intelligence under the Sichuan Medical Association; Standing Committee Member of the Laparoscopic and Robotic Surgery Branch of the China Anti-Cancer Association; National Committee Member of the Medical Robotics Physicians Branch, the Endoscopists Branch, the Urological Laparoscopy Professional Committee, and the Minimally Invasive and Non-invasive Medicine (Urology) Professional Committee under the Chinese Medical Doctor Association; Youth Committee Member of the Urology Branch of the Chinese Medical Association; National Committee Member of the Urogenital Tumor Professional Committee and the Minimally Invasive Surgery Group of the China Anti-Cancer Association; Committee Member of the Urology Professional Committee under the Chinese Research Hospital Association and the Cross-Strait Medical and Health Exchange Association; Committee Member of the Enhanced Recovery After Surgery (ERAS) Professional Committee under the China Medicine Education Association; Committee Member of the Urology Professional Committee under the Sichuan Medical Association and Deputy Leader of its Minimally Invasive Urology Group; Committee Member of the China Urology and Andrology Medical Technology and Equipment Innovation Alliance, the Bladder Cancer Diagnosis and Treatment Peak Alliance, and the Urological Reconstruction Alliance; Designated as one of the first batch of Laparoscopic Training Bases for Urology Departments in County-level Hospitals by the Chinese Medical Association; Executive Director of the Sichuan Clown Doctors Public Welfare and Charity Promotion Association; Council Member of the First Council of the China Medical Equipment Artificial Intelligence Alliance; The first globally registered Da Vinci surgeon in Sichuan Province, having performed over 1,000 robotic surgeries.

Gong Xiangyang——Deputy Dean, School of Medical Imaging, Hangzhou Medical College

Gong Xiangyang, Deputy Dean and Professor at the School of Medical Imaging, Hangzhou Medical College; Director and Chief Physician of the Department of Radiology, Zhejiang Provincial People’s Hospital. As one of the earliest radiology experts in China to engage with artificial intelligence in medical imaging, his pioneering work has been featured by CCTV, The New York Times, and various online and print media outlets.

Those interested in attending the "Forum on Capital Empowering the Industrial Upgrade of Medical AI" may[Click here to register directly]Or scan the QR code below to register!